World Economic Forum Grants AgroAmerica the New Champions Award
AgroAmerica received the New Champions Award 2021 – in the category of Excellence in Social Responsibility for the Human Development Center -HDC- project, which consists of a medical clinic, research facility, and a school for worker's children, promoting health, education, and development in the Southwestern region of Guatemala.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006209/en/
AgroAmerica’s Human Development Center project received the New Champions Award 2021 endorsed by the World Economic Forum in the category of Excellence in Social Responsibility. A project built in 10ha of land donated by AgroAmerica for the construction of a Medical Clinic, Research Center and school for worker’s children in Southwestern Guatemala. (Photo: Business Wire)
Since its opening in 2014, the Center has been managed in alliance comprising the University of Colorado, Project Cure, Foundation for the Comprehensive Health of Guatemalans – Funsalud- and Agroamerica, aiming to contribute to the Sustainable Development Goals .
To date, the clinic has provided a range of services for more than 35,000 patients, including medical treatments, dental care, and a childbirth center. The community programs focus on mother and child health and youth development; from 2014 to 2020, 3,343 children and 1,976 women have participated in the programs to decrease maternal and infant mortality and improve the nutritional status of the area; the local level of child malnourishment has been dramatically reduced from the national average of 50% .
The Research Center complements the actions of the HDC. The main objective is to scientifically investigate the root causes of the health problems observed in the region by measuring the incidence of diseases such as Zika, Chikungunya, Dengue, diarrhea, and most recently, COVID-19, to develop action plans to eradicate them.
"We are beyond honored," said Fernando Bolaños, AgroAmerica CEO. "Recognitions like these move and inspire other organizations, companies, and individuals to join and act to positively impact our environment and set worldwide standards for sustainable business, corporate governance, innovation, and social responsibility. Congratulations to all the New Champions!"
WEF New Champions
World Economic Forum New Champion companies are dynamic high-growth companies that are championing new business models, emerging technologies, and sustainable growth strategies in the Fourth Industrial Revolution.
The New Champions award is an initiative to identify and reward exceptional efforts by members of the New Champions Community in sending strong market signals and scaling innovative solutions for revitalizing our societies, accelerating technology and innovation, and promoting responsible corporate governance. See World Economic Forum’s New Champions award announcement here.
About AgroAmerica:
AgroAmerica is a family-owned, diversified, and vertically integrated Corporation in the agro-industrial production, processing, commercialization, and distribution of sustainable food and ingredients of the highest quality committed to contributing to the well-being of people and nature through Corporate Social Responsibility. https://agroamerica.com/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006209/en/
Contact information
Javier Aguirre
sustainability@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom